Selank and Anxiety: Results of a Phase III Clinical Trial for Generalized Anxiety Disorder
Semenova TP, Kozlovskaya MM, Zuikov AV, Narkevich VB
Bulletin of Experimental Biology and Medicine · Vol. 149(3) · pp. 316–319 · 2010
Phase III clinical trial demonstrating Selank's efficacy in generalized anxiety disorder. The peptide showed anxiolytic effects comparable to benzodiazepines without dependence, tolerance, or sedation. Selank modulates the GABAergic system and enkephalin metabolism, providing a unique mechanism distinct from conventional anxiolytics.
Citation
Key Findings
Selank reduced anxiety scores comparable to benzodiazepine controls
No dependence, tolerance, or withdrawal effects observed
Improves cognitive function and memory alongside anxiolytic effects
Well tolerated with minimal side effects in 62 patients
Modulates IL-6 expression, suggesting immune-cognitive interaction
Methodology
Randomized controlled Phase III trial in 62 patients with generalized anxiety disorder. Compared Selank to standard anxiolytic treatment over 14 days with validated anxiety rating scales.
Limitations
Relatively small sample size. Short treatment duration. Limited replication outside Russian research institutions.
Protocols Using This Research
Tags
Educational use only. Research summaries are provided for informational purposes. Always consult the original publication and a qualified healthcare provider before making clinical decisions.
Related Research
Build a protocol around this research
Our AI Advisor incorporates the latest research to build a personalized peptide protocol for your goals.
Start Assessment